Larimar Therapeutics (NASDAQ:LRMR) Stock Gets Downgrade from Wall Street Zen

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday, Wall Street Zen reports.

Other equities analysts have also issued reports about the company. Wedbush reiterated an “outperform” rating on shares of Larimar Therapeutics in a research report on Tuesday, November 10th. Leerink Partners began coverage on Larimar Therapeutics in a research report on Monday, September 14th. They issued an “outperform” rating and a $13.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $10.33.

View Our Latest Research Report on Larimar Therapeutics

Larimar Therapeutics Price Performance

Shares of LRMR stock opened at $3.02 on Friday. The business has a 50-day moving average price of $2.93 and a two-hundred day moving average price of $3.76. Larimar Therapeutics has a 12-month low of $1.91 and a 12-month high of $6.42. The firm has a market cap of $313.73 million, a P/E ratio of -1.55 and a beta of 0.73.

Insider Activity

In other news, CFO Michael Celano purchased 18,460 shares of the business’s stock in a transaction on Wednesday, November 11th. The shares were acquired at an average price of $2.71 per share, with a total value of $50,026.60. Following the acquisition, the chief financial officer directly owned 234,245 shares in the company, valued at approximately $634,803.95. The trade was a 8.55% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Carole Ben-Maimon acquired 18,050 shares of the firm’s stock in a transaction on Wednesday, November 11th. The stock was purchased at an average price of $2.77 per share, for a total transaction of $49,998.50. Following the transaction, the chief executive officer directly owned 386,326 shares of the company’s stock, valued at approximately $1,070,123.02. This trade represents a 4.90% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders acquired 140,810 shares of company stock worth $381,955. 4.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Larimar Therapeutics

Institutional investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC purchased a new position in Larimar Therapeutics during the 2nd quarter valued at about $27,000. Pallas Capital Advisors LLC bought a new position in Larimar Therapeutics during the 2nd quarter valued at approximately $31,000. HB Wealth Management LLC purchased a new stake in Larimar Therapeutics in the 2nd quarter worth approximately $49,000. Sei Investments Co. lifted its holdings in Larimar Therapeutics by 54.5% in the 1st quarter. Sei Investments Co. now owns 16,336 shares of the company’s stock worth $74,000 after buying an additional 5,763 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new stake in Larimar Therapeutics in the 2nd quarter worth approximately $60,000. 91.92% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Larimar Therapeutics

Here are a few of the latest headlines about LRMR:

  • Positive Sentiment: CEO Carole Ben-Maimon, CFO Michael Celano, COO John B. Jr. Harlow, insider Gopi Shankar, and directors Frank Thomas and Joseph Truitt together purchased 52,810 shares for roughly $195,000. Director Thomas Hamilton separately bought 70,000 shares for $186,900. Insider purchase report Hamilton SEC filing
  • Neutral Sentiment: The supplied coverage also notes H.C. Wainwright maintained a Buy rating; no rating change or fresh price-moving catalyst was reported. Analyst rating report

About Larimar Therapeutics

(Get Free Report)

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

Further Reading

Analyst Recommendations for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.